{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:38:11Z","timestamp":1788043091150,"version":"build-2784847793"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","award":["R21CA280433"],"award-info":[{"award-number":["R21CA280433"]}],"id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA280433"],"award-info":[{"award-number":["R21CA280433"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UM1TR004405"],"award-info":[{"award-number":["UM1TR004405"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA77598"],"award-info":[{"award-number":["P30 CA77598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021163","name":"Children's Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100120","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T18:20:38Z","timestamp":1747678838000},"page":"100120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-1881","authenticated-orcid":false,"given":"Peter M.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-5286","authenticated-orcid":false,"given":"Robin L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ostergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9580-534X","authenticated-orcid":false,"given":"Keegan C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3817-050X","authenticated-orcid":false,"given":"Hannah N.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-4598","authenticated-orcid":false,"given":"Joseph M.","family":"Muretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-4450","authenticated-orcid":false,"given":"Bridget S.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2278-5054","authenticated-orcid":false,"given":"Thomas","family":"Beder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7494-9859","authenticated-orcid":false,"given":"Luke","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-0478","authenticated-orcid":false,"given":"Benjamin E.","family":"Deonovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-1662","authenticated-orcid":false,"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-7727","authenticated-orcid":false,"given":"Stuart S.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.bneo.2025.100120_bib1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100120_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100120_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.21037\/tp-22-656","article-title":"Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies","volume":"12","author":"Munir","year":"2023","journal-title":"Transl Pediatr"},{"key":"10.1016\/j.bneo.2025.100120_bib4","article-title":"Immunotherapy for pediatric acute lymphoblastic leukemia: recent advances and future perspectives","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100120_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.humimm.2019.01.011","article-title":"Immunotherapy in pediatric B-cell acute lymphoblastic leukemia","volume":"80","author":"Wyatt","year":"2019","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100120_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-017-0380-3","article-title":"New therapeutic strategies in acute lymphocytic leukemia","volume":"12","author":"Man","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.bneo.2025.100120_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11899-018-0457-7","article-title":"Novel therapies in acute lymphoblastic leukemia","volume":"13","author":"Phelan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bneo.2025.100120_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.923419","article-title":"Novel treatments for pediatric relapsed or refractory acute B-cell lineage lymphoblastic leukemia: precision medicine era","volume":"10","author":"Mengxuan","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.bneo.2025.100120_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.bneo.2025.100120_bib10","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.bneo.2025.100120_bib11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100120_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"issue":"10","key":"10.1016\/j.bneo.2025.100120_bib13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bneo.2025.100120_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.bneo.2025.100120_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.bneo.2025.100120_bib16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2025.100120_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237738","article-title":"Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations","volume":"14","author":"Rubinstein","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100120_bib18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14712598.2015.1041912","article-title":"Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies","volume":"15","author":"Rogala","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.bneo.2025.100120_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bneo.2025.100120_bib21","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.3389\/fimmu.2018.02423","article-title":"The role of the pre-B cell receptor in B cell development, repertoire selection, and tolerance","volume":"9","author":"Winkler","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100120_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2007.02.006","article-title":"The pre-B-cell receptor","volume":"19","author":"M\u00e5rtensson","year":"2007","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100120_bib23","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood.V99.7.2459.h8002459_2459_2467","article-title":"Differential surrogate light chain expression governs B-cell differentiation","volume":"99","author":"Wang","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100120_bib24","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1172\/JCI78083","article-title":"Checkpoints that control B cell development","volume":"125","author":"Melchers","year":"2015","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.bneo.2025.100120_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000939","article-title":"The gene expression classifier ALLCatchR identifies B-cell precursor ALL subtypes and underlying developmental trajectories across age","volume":"7","author":"Beder","year":"2023","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.bneo.2025.100120_bib25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/bloodadvances.2021005245","article-title":"VpreB surrogate light chain expression in B-lineage ALL: a report from the Children\u2019s Oncology Group","volume":"6","author":"Winter","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2025.100120_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bneo.2025.100120_bib27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice","volume":"29","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bneo.2025.100120_bib28","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1172\/JCI134424","article-title":"Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL","volume":"130","author":"Hurtz","year":"2020","journal-title":"J Clin Invest"},{"issue":"456","key":"10.1016\/j.bneo.2025.100120_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaf3949","article-title":"Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia","volume":"9","author":"Erasmus","year":"2016","journal-title":"Sci Signal"},{"issue":"8","key":"10.1016\/j.bneo.2025.100120_bib30","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood.V98.8.2498","article-title":"Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry","volume":"98","author":"McKenna","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100120_bib31","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/2159-8290.CD-20-1230","article-title":"St. Jude cloud: a pediatric cancer genomic data-sharing ecosystem","volume":"11","author":"McLeod","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.bneo.2025.100120_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"issue":"3","key":"10.1016\/j.bneo.2025.100120_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccell.2015.02.003","article-title":"Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia","volume":"27","author":"Geng","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bneo.2025.100120_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.bneo.2025.100120_bib35","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s10529-016-2160-x","article-title":"Antibody drug conjugates","volume":"38","author":"Bakhtiar","year":"2016","journal-title":"Biotechnol Lett"},{"issue":"6","key":"10.1016\/j.bneo.2025.100120_bib36","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100120_bib37","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100120_bib38","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"Dijoseph","year":"2007","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bneo.2025.100120_bib39","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1158\/1078-0432.CCR-04-1134","article-title":"Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma","volume":"10","author":"DiJoseph","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.bneo.2025.100120_bib40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100120_bib41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2014.04.005","article-title":"Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development","volume":"157","author":"Bendall","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bneo.2025.100120_bib42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nm.4505","article-title":"Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse","volume":"24","author":"Good","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.bneo.2025.100120_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12235","article-title":"Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia","volume":"263","author":"Buchner","year":"2015","journal-title":"Immunol Rev"},{"issue":"24","key":"10.1016\/j.bneo.2025.100120_bib44","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1182\/blood-2015-01-567842","article-title":"Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia","volume":"125","author":"M\u00fcschen","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100120_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MOH.0000000000000048","article-title":"Targeting the B-cell receptor signaling pathway in B lymphoid malignancies","volume":"21","author":"Buchner","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100120_bib46","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","article-title":"Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia","volume":"22","author":"Bicocca","year":"2012","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bneo.2025.100120_bib47","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood-2016-06-722900","article-title":"Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100120_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2643-3249.BCD-20-0078","article-title":"MEF2D fusions drive oncogenic pre-BCR signaling in B-ALL","volume":"1","author":"Sadras","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.bneo.2025.100120_bib49","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/leu.2016.9","article-title":"Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K\/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition","volume":"30","author":"K\u00f6hrer","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bneo.2025.100120_bib50","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/sj.onc.1209133","article-title":"BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells","volume":"25","author":"Klein","year":"2006","journal-title":"Oncogene"},{"issue":"37","key":"10.1016\/j.bneo.2025.100120_bib51","doi-asserted-by":"crossref","first-page":"13266","DOI":"10.1073\/pnas.0505196102","article-title":"Deficiency of Bruton\u2019s tyrosine kinase in B cell precursor leukemia cells","volume":"102","author":"Feldhahn","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.bneo.2025.100120_bib52","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20031637","article-title":"The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells","volume":"199","author":"Klein","year":"2004","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.bneo.2025.100120_bib53","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1084\/jem.20090004","article-title":"Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function","volume":"206","author":"Trageser","year":"2009","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.bneo.2025.100120_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/jamaoncol.2021.2723","article-title":"Association of combined focal 22q11.22 deletion and IKZF1 alterations with outcomes in childhood acute lymphoblastic leukemia","volume":"7","author":"Mangum","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100120_bib55","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.bneo.2025.100120_bib56","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bneo.2025.100120_bib57","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000754","article-title":"Preclinical evidence for the efficacy of CD79b immunotherapy in B-cell precursor acute lymphoblastic leukemia","volume":"6","author":"Lenk","year":"2022","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.bneo.2025.100120_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802500055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:05Z","timestamp":1778938625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032802500055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S295032802500055X"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100120","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100120"}}